Study	total number	Proportion (%)	95% CI
Stelloo et al. 2016	219	61.644	54.853 to 68.115
An et al. 2007	17	70.588	44.042 to 89.686
Black et al. 2006	93	77.419	67.578 to 85.446
Kommoss et al. 2018	127	80.315	72.328 to 86.837
Mackay et al. 2010	32	65.625	46.807 to 81.428
Mills et al. 2014	40	65.000	48.316 to 79.372
Djordjevic et al. 2013	46	60.870	45.374 to 74.912
Ruiz et al. 2014	64	90.625	80.703 to 96.481
Talhouk et al. 2016	16	62.500	35.435 to 84.802
Talhouk et al. 2017	64	18.750	10.082 to 30.462
Total (fixed effects)	718	66.763	63.209 to 70.179
Total (random effects)	718	65.718	52.602 to 77.714
Q	108.4822		
DF	9		
Significance level	P < 0.001		
I^2 (inconsistency)	91.70%		

(A)

Study	Sample size	Proportion (%)	95% CI
Stelloo et al. 2016	834	26.259	23.301 to 29.386
An et al. 2007	100	17.000	10.226 to 25.818
Black et al. 2006	473	19.662	16.173 to 23.534
Kommoss et al. 2018	452	28.097	23.998 to 32.486
Mackay et al. 2010	163	19.632	13.833 to 26.569
Mills et al. 2014	605	6.612	4.765 to 8.895
Djordjevic et al. 2013	186	24.731	18.711 to 31.575
Ruiz et al. 2014	212	30.189	24.090 to 36.851
Talhouk et al. 2016	57	28.070	16.973 to 41.543
Talhouk et al. 2017	319	20.063	15.807 to 24.884
Total (fixed effects)	3401	20.479	19.135 to 21.872
Total (random effects)	3401	21.529	15.930 to 27.718
Q		151.1757	
DF		9	
Significance level		P < 0.001	
I^2 (inconsistency)		94.050%	
95% CI for I^2		90.970 to 96.080	

(B)

Supplementary Fig. S9. Grade analysis in mismatch repair deficiency in endometrial carcinoma [2,3,13,15,16,18,19,21,24,25]: (A) grade I–II and (B) grade III. CI, confidence interval.